home / stock / mpsyf / mpsyf short
Short Information | Morphosys Ag Ord (OTCMKTS:MPSYF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 14,987 |
Total Actual Volume | 705,648 |
Short Trends | |
---|---|
Cover Days | 9 |
Short Days | 11 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 749 |
Average Short Percentage | 54.56% |
Is there a MPSYF Short Squeeze or Breakout about to happen?
See the MPSYF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
03-22-2024 | $0 | $71.38 | $0 | $0 | 40 | 40 | 100% |
03-21-2024 | $0 | $71.38 | $0 | $0 | 7,523 | 23 | 0.31% |
03-20-2024 | $0 | $71.38 | $0 | $0 | 23 | 23 | 100% |
03-18-2024 | $0 | $71.38 | $0 | $0 | 6 | 4 | 66.67% |
03-15-2024 | $0 | $71.38 | $0 | $0 | 8 | 8 | 100% |
03-14-2024 | $71.38 | $71.38 | $71.38 | $71.38 | 256 | 55 | 21.48% |
03-12-2024 | $72.71 | $72.71 | $72.71 | $72.71 | 108 | 108 | 100% |
02-09-2024 | $70.28 | $70.28 | $70.28 | $70.28 | 106 | 100 | 94.34% |
02-06-2024 | $70.659 | $65.69 | $70.659 | $65.69 | 672,056 | 9,904 | 1.47% |
02-05-2024 | $46 | $69.29 | $69.29 | $45.93 | 19,900 | 2,400 | 12.06% |
02-02-2024 | $45.57 | $44.4 | $46.21 | $44.4 | 800 | 100 | 12.5% |
02-01-2024 | $44.72 | $45.62 | $45.62 | $44.72 | 300 | 300 | 100% |
01-30-2024 | $44.11 | $44.68 | $44.69 | $44.11 | 300 | 100 | 33.33% |
01-29-2024 | $43.05 | $43.6 | $43.6 | $42.16 | 522 | 122 | 23.37% |
01-26-2024 | $41.26 | $43.48 | $43.91 | $41.26 | 600 | 500 | 83.33% |
01-22-2024 | $36.43 | $36.63 | $36.63 | $36.43 | 200 | 200 | 100% |
01-19-2024 | $36.44 | $35.98 | $36.44 | $35.67 | 800 | 100 | 12.5% |
01-18-2024 | $42.16 | $40.83 | $42.16 | $40.15 | 700 | 100 | 14.29% |
01-17-2024 | $44.76 | $43.42 | $44.76 | $43.42 | 500 | 300 | 60% |
01-16-2024 | $36.65 | $42.44 | $42.44 | $36.65 | 900 | 500 | 55.56% |
News, Short Squeeze, Breakout and More Instantly...
Morphosys Ag Ord Company Name:
MPSYF Stock Symbol:
OTCMKTS Market:
Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 24, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new efficacy and safety data from the Phase 3 MANIFEST-2 trial of pel...
Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion Shareholders benefit from attractive premium of 94% and 142% on the volume-weighted average price during the last month and three months before January 25, 2024, respectively Acce...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 22, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") in connection with the proposed acquisition of MorphoSys by Novart...